Addiction, Author Interviews, Opiods / 24.06.2021
SUBLOCADE® (buprenorphine extended-release) in Patients Who Inject Opioids
MedicalResearch.com: What is the background for this study?
Response: Adults with moderate or severe opioid use disorder (OUD) were randomized to SUBLOCADE monthly injections or placebo and studied for 24 weeks.
Participants receiving SUBLOCADE were given 2 monthly injections of 300 mg, followed by 4 monthly maintenance doses of 100 mg or 300 mg over the course of the study.
(more…)